AU752676B2 - Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues - Google Patents
Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues Download PDFInfo
- Publication number
- AU752676B2 AU752676B2 AU94410/98A AU9441098A AU752676B2 AU 752676 B2 AU752676 B2 AU 752676B2 AU 94410/98 A AU94410/98 A AU 94410/98A AU 9441098 A AU9441098 A AU 9441098A AU 752676 B2 AU752676 B2 AU 752676B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- site
- monocyte derived
- agents
- derived cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/414—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/924,830 US20020068048A1 (en) | 1997-09-05 | 1997-09-05 | Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues |
| US08/924830 | 1997-09-05 | ||
| PCT/EP1998/005707 WO1999013054A2 (en) | 1997-09-05 | 1998-08-31 | Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU9441098A AU9441098A (en) | 1999-03-29 |
| AU752676B2 true AU752676B2 (en) | 2002-09-26 |
Family
ID=25450795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU94410/98A Ceased AU752676B2 (en) | 1997-09-05 | 1998-08-31 | Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20020068048A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1009806A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2001515713A (cg-RX-API-DMAC10.html) |
| AU (1) | AU752676B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2300387A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL134393A0 (cg-RX-API-DMAC10.html) |
| WO (1) | WO1999013054A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000060054A1 (en) * | 1999-04-06 | 2000-10-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof |
| AU1375301A (en) * | 1999-11-15 | 2001-05-30 | Bio Syntech Canada Inc | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
| AU5159901A (en) * | 2000-04-14 | 2001-10-30 | Univ Pittsburgh | Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof |
| EP1335687B1 (en) * | 2000-11-15 | 2007-01-10 | Bio Syntech Canada Inc. | Method for restoring a damaged or degenerated intervertebral disc |
| KR101114784B1 (ko) | 2002-11-12 | 2012-02-27 | 예일 유니버시티 | 아데노바이러스 벡터 백신 |
| ATE482713T1 (de) * | 2003-04-25 | 2010-10-15 | Univ Pittsburgh | Von muskeln stammende zellen (mdcs) zur förderung und verbesserung der nervenreparatur und - regeneration |
| US8986736B2 (en) | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
| US9044381B2 (en) | 2003-06-24 | 2015-06-02 | Baxter International Inc. | Method for delivering drugs to the brain |
| RU2006144851A (ru) | 2004-06-15 | 2008-06-20 | Бакстер Интернэшнл Инк. (Us) | Применение терапевтических средств ex-vivo в виде твердых микрочастиц |
| US20100178355A1 (en) * | 2006-11-30 | 2010-07-15 | Hoemann Caroline D | Method for in situ solidification of blood-polymer compositions for regenerative medicine and cartilage repair applications |
| RU2496482C2 (ru) | 2008-03-05 | 2013-10-27 | Бакстер Интернэшнл Инк. | Композиции и способы для доставки лекарственных средств |
| EP2328596B1 (en) * | 2008-08-18 | 2019-03-06 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof |
| US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| GB201504251D0 (en) | 2015-03-13 | 2015-04-29 | Virttu Biolog Ltd And University Of Sheffield The | Oncolytic herpes simplex virus infected cells |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7539894A (en) * | 1993-08-25 | 1995-03-21 | Institut National De La Sante Et De La Recherche Medicale | Recombinant cells from the monocyte-macrophage cell line for gene therapy |
| AU4626596A (en) * | 1995-01-24 | 1996-08-14 | I.D.M. Immuno-Designed Molecules | Process for preparing macrophages, and kits and compositions therefore |
-
1997
- 1997-09-05 US US08/924,830 patent/US20020068048A1/en not_active Abandoned
-
1998
- 1998-08-31 IL IL13439398A patent/IL134393A0/xx unknown
- 1998-08-31 EP EP98947533A patent/EP1009806A2/en not_active Ceased
- 1998-08-31 JP JP2000510843A patent/JP2001515713A/ja active Pending
- 1998-08-31 WO PCT/EP1998/005707 patent/WO1999013054A2/en not_active Ceased
- 1998-08-31 CA CA002300387A patent/CA2300387A1/en not_active Abandoned
- 1998-08-31 AU AU94410/98A patent/AU752676B2/en not_active Ceased
-
2004
- 2004-01-30 US US10/766,929 patent/US20050048039A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7539894A (en) * | 1993-08-25 | 1995-03-21 | Institut National De La Sante Et De La Recherche Medicale | Recombinant cells from the monocyte-macrophage cell line for gene therapy |
| AU4626596A (en) * | 1995-01-24 | 1996-08-14 | I.D.M. Immuno-Designed Molecules | Process for preparing macrophages, and kits and compositions therefore |
Non-Patent Citations (1)
| Title |
|---|
| GENE THERAPY, 1996, 3(1), PARRISH ET AL., 13-20 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL134393A0 (en) | 2001-04-30 |
| WO1999013054A3 (en) | 1999-05-06 |
| JP2001515713A (ja) | 2001-09-25 |
| US20050048039A1 (en) | 2005-03-03 |
| CA2300387A1 (en) | 1999-03-18 |
| AU9441098A (en) | 1999-03-29 |
| WO1999013054A2 (en) | 1999-03-18 |
| US20020068048A1 (en) | 2002-06-06 |
| EP1009806A2 (en) | 2000-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gravel et al. | Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons | |
| Tai et al. | Gene transfer of glial cell line-derived neurotrophic factor promotes functional recovery following spinal cord contusion | |
| Frautschy et al. | Localization of basic fibroblast growth factor and its mRNA after CNS injury | |
| Sagot et al. | Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse | |
| AU772340B2 (en) | Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells | |
| Kramer et al. | Gene transfer through the blood–nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis | |
| Lu et al. | Overexpression of CNTF in Mesenchymal Stem Cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice | |
| CN102886052B (zh) | 长效药物制剂 | |
| Finiels et al. | Specific and efficient gene transfer strategy offers new potentialities for the treatment of motor neurone diseases | |
| Lu et al. | Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport | |
| US20050048039A1 (en) | Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues | |
| JPH11507201A (ja) | 筋肉の疾患および障害の治療方法 | |
| US20240108652A1 (en) | Enhancing metabolic fitness of t cells to treat cancer | |
| US12343420B2 (en) | Stabilized polyribonucleotide coding for an elastic fibrous protein | |
| Cunningham et al. | Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease | |
| US6451306B1 (en) | Methods for therapy of neurodegenerative disease of the brain | |
| Martinez‐Serrano et al. | Ex vivo gene transfer of brain‐derived neurotrophic factor to the intact rat forebrain: neurotrophic effects on cholinergic neurons | |
| Bankiewicz et al. | Practical Aspects of the Development ofex Vivoandin VivoGene Therapy for Parkinson's Disease | |
| Barami et al. | Cellular transplantation and spinal cord injury | |
| KR20010093804A (ko) | 심근증 유전자 치료 | |
| US20020187936A1 (en) | Methods of treating liver disease and liver damage with growth hormone and foxM1B | |
| Kato et al. | Nonviral HVJ (hemagglutinating virus of Japan) liposome-mediated retrograde gene transfer of human hepatocyte growth factor into rat nervous system promotes functional and histological recovery of the crushed nerve | |
| Joung et al. | Effective Gene Transfer into Regenerating Sciatic Nerves by Adenoviral Vectors: Potentials for Gene Therapy of Peripheral Nerve Injury: Insil Joung et al. | |
| JP2001515713A5 (cg-RX-API-DMAC10.html) | ||
| Tuszynski et al. | Somatic gene transfer to the adult primate central nervous system: in vitroandin vivocharacterization of cells genetically modified to secrete nerve growth factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |